December 2nd 2024
If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Mole-atopic dermatitis relationship reversed in children
October 1st 2002Los Angeles - Among 3-year-olds, children with atopic dermatitis have significantly more melanocytic nevi than their unaffected counterparts, and the difference in nevi count overall can be accounted for by higher numbers of nevi present in light-skinned children with eczema, Robert Dellavalle, M.D., Ph.D., said at the annual meeting of the Society for Investigative Dermatology.
Tacrolimus ointment tackles signs of seborrheic dermatitis
October 1st 2002Paris - Results from a small pilot study suggest that topical tacrolimus ointment 0.1 percent (Protopic) may be a promising new treatment for seborrheic dermatitis, researchers from Emory University School of Medicine, Atlanta, reported.
Skin substitutes valuable for hard-to-heal wounds
September 15th 2002Paris - Bioengineered skin substitutes can facilitate healing of difficult wounds and even achieve closure of some long-standing chronic wounds refractory to other measures, but the success of these modalities depends on proper wound bed preparation and even then, they may not be the answer for all patients, Vincent Falanga, M.D., said at the World Congress of Dermatology.
Itraconazole use covers various inflammatory diseases
September 15th 2002New Orleans - Disorders that seemingly have no mycotic component could respond to a course of itraconazole (Sporanox), according to Ruggero Caputo, M.D. In fact, for certain patients, it may have a role in the treatment of inflammatory diseases such seborrheic dermatitis, atopic dermatitis, and rosacea, as well as palmo plantar amicrobic pustulosis.
Congenital nevi now have broader definition
September 1st 2002New Orleans -The management of congenital nevi is an extremely challenging and easily misunderstood area for dermatologists. New insights into the disorder were shared at the annual meeting of the American Academy of Dermatology by a specialist in the field, Ashfaq A. Marghoob, M.D., assistant professor of dermatology, Memorial Sloan-Kettering Cancer Center, New York.
Standard dogma still holds: Remove nevus sebaceous prior to onset of adolescence
September 1st 2002New Orleans - While the risk of malignant conversion of nevus sebaceous has been a subject of recent controversy, pediatric dermatologist Sheila Fallon Friedlander, M.D., still recommends prophylactic surgical excision of such lesions prior to adolescence.
Diminished inflammation combats skin aging
September 1st 2002Chicago - A three-tiered program to reduce inflammation in the body on a cellular level includes a diet rich in antioxidants, antioxidant supplements, and topical preparations that will deliver unique antioxidants directly to the skin, according to research performed by dermatologist Nicholas Perricone, M.D.
Azathioprine efficacy is "gold standard" in trial
September 1st 2002Los Angeles - Azathioprine is an effective treatment for severe atopic dermatitis in adults, although it can be poorly tolerated by some patients due to gastrointestinal side effects, and careful laboratory monitoring is indicated because of its potential to cause hematologic and hepatic toxicity, according to results of a randomized, double-blind, placebo-controlled, crossover study.
Growing Latino population has intricacies
August 1st 2002New York-The incidence of skin disease is not significantly different among Latinos than with other patient groups, but physicians who treat Latino patients need to be aware of some differences in the frequency of diagnosis as well as the cultural aspects of treatment, Miguel R. Sanchez, M.D., said.
Asian patients new to U.S. require special attention
August 1st 2002New York - Awareness and sensitivity about beliefs and cultural practices are important tools in treating the Asian population - especially those that are newly immigrated, Henry W. Lim, M.D., said at the annual meeting of The Skin of Color Center, St. Luke's Roosevelt Hospital Center, New York.
Clothes, targeted Tx lessen disorders in African American kids
August 1st 2002New York - The good news is that African American children do not need to change their hairstyles to minimize their risk for tinea capitis infections. But a change of wardrobe - to one that eliminates button-fly pants, garments with metal grommets, etc. - is definitely in order to prevent severe allergic reactions to nickel, Nanette Silverberg, M.D., said at the annual meeting of The Skin of Color Center, St. Luke's-Roosevelt Hospital Center, New York.
Oral antihistamines not a cure for all cutaneous itching
August 1st 2002New Orleans - As antipruritic drugs, newer second-generation oral antihistamines, including loratadine (Claritin), cetirizine (Zyrtec), fexofenadine (Allegra), and desloratadine (Clarinex), offer several advantages compared with their predecessors. However, clinicians should be aware that these newer compounds are neither all alike nor routinely effective for controlling all types of cutaneous itch, Michael D. Tharp, M.D., said at the annual meeting of the American Academy of Dermatology.
Searching for scientific support in AD research
July 1st 2002New Orleans - Atopic dermatitis is a frustrating condition to treat,and many frequently employed interventions lack scientific support. Thiswas the rationale behind a systematic review of all randomized, controlledtrials of AD conducted by the United Kingdom Department of Health and presentedat the American Academy of Dermatology annual meeting by Hywel Williams,Ph.D.